The IMNM Research Grant from The Myositis Association funds innovative research into the causes, mechanisms, and treatment of immune-mediated necrotizing myopathy to improve patient outcomes.
Funder: The Myositis Association
Due Dates (Anticipated): May 2027 (Letter of Intent) | June 2027 (Full application)
Funding Amounts: Up to $150,000 total; project period 24–36 months; includes $5,000 for travel.
Summary: Supports innovative research advancing understanding, treatment, and quality of life for those with immune-mediated necrotizing myopathy (IMNM).
This grant supports research projects focused on immune-mediated necrotizing myopathy (IMNM), with the goal of advancing knowledge of disease mechanisms, causes, and the development of new therapies or quality-of-life improvements for affected individuals. Projects may address IMNM subtypes (such as anti-HMGCR, anti-SRP, or others), explore intersections with related idiopathic inflammatory myopathies, and investigate interventions for symptoms like muscle weakness, mobility challenges, pain, fatigue, and pulmonary function. The program encourages collaborative, interdisciplinary, and patient-centered research, prioritizing studies likely to yield new or improved treatment options or enhance daily living for people with IMNM.